Digital therapeutics — software-based interventions that prevent, manage, or treat medical conditions through evidence-based mechanisms — represent one of the most complex commercialization challenges in health technology. Companies in this space must demonstrate clinical efficacy through rigorous trials, obtain regulatory authorization or clearance, negotiate coverage with payers, and educate prescribers about a category of treatment that most were not trained to prescribe.
The global digital therapeutics market was valued at $7.8 billion in 2022 and is projected to reach $56.4 billion by 2030, according to Grand View Research, growing at a CAGR of 28.4%. But getting to that market requires extraordinary operational execution from companies that are often still in the single-digit headcount range.
Virtual assistants are helping digital therapeutics companies punch above their weight during the critical commercialization phase.
The Commercialization Burden Is Unlike Any Other Health Tech Segment
Unlike a SaaS health IT company that can sell directly to a hospital IT department, a digital therapeutics company must simultaneously pursue multiple parallel commercialization tracks. Regulatory affairs must manage FDA interactions. Market access must build the evidence dossiers that justify payer coverage decisions. Medical affairs must train prescribers on how to identify and refer appropriate patients. Business operations must support all of the above.
A 2023 Digital Therapeutics Alliance report noted that the average DTx company takes 18 to 24 months from FDA authorization to meaningful commercial revenue — largely because the multi-track commercialization process is so operationally demanding. Companies that can execute all tracks simultaneously, rather than sequentially, reach sustainable revenue faster.
Virtual assistants enable that parallel execution.
VA Applications Across the DTx Commercialization Lifecycle
Regulatory Affairs Administrative Support
FDA 510(k) clearances, De Novo requests, and Breakthrough Device Designation applications require extensive documentation. VAs support the regulatory affairs team with document formatting, submission checklist management, FDA correspondence tracking, and maintaining organized regulatory archives. When additional clearances are needed for new indications or markets, VAs manage the administrative pipeline that keeps the submission process moving.
Payer Outreach and Coverage Documentation Coordination
Securing payer coverage for a digital therapeutic requires developing formal health technology assessment dossiers, submitting coverage applications, and following up through multi-level payer review processes. VAs can track submission timelines, manage correspondence with payer medical policy teams, compile value evidence packages, and coordinate meetings between market access leads and payer clinical staff.
Prescriber Education and Medical Affairs Support
Getting physicians to prescribe a digital therapeutic requires education about the clinical evidence, the prescription process, and patient support resources. VAs can coordinate continuing medical education logistics, manage speaker programs, track prescriber engagement in CRM systems, prepare educational materials for medical affairs review, and handle the scheduling and follow-up for medical science liaison interactions.
Clinical Study Operations Support
Many digital therapeutics companies conduct ongoing clinical studies to expand their evidence base and support new indications. VAs assist with study coordination tasks — scheduling site visits, maintaining site documentation, processing data collection forms, and coordinating with IRB administrative contacts. This allows clinical operations staff to focus on site management and data quality rather than scheduling and documentation logistics.
Maximizing Every Dollar in a Capital-Intensive Space
Digital therapeutics development is capital-intensive. Clinical trials, regulatory affairs, and payer engagement all require significant investment before a dollar of commercial revenue is recognized. Companies that can extend the runway of their capital by operating more efficiently — through VA support for administrative functions — can achieve commercial milestones that open the next funding round or profitability path.
Digital therapeutics companies looking to accelerate commercialization without adding to fixed headcount can explore experienced VA solutions at https://www.stealthagents.com, where virtual assistants are matched to health technology companies based on their specific operational needs.
The Race to Commercial Scale
In digital therapeutics, the companies that get to sustainable commercial revenue first will define the category. Virtual assistants are a direct lever on the speed of that journey — enabling small teams to execute complex multi-track commercialization strategies with the operational discipline of much larger organizations.
Sources
- Grand View Research: Digital Therapeutics Market Size, Share & Trends Analysis, 2023–2030
- Digital Therapeutics Alliance: DTx Commercialization Timeline Benchmarks, 2023
- IQVIA Institute for Human Data Science: Digital Health Trends 2023